Abstract
Purpose
The aim of the INSTINCT trial was to assess the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo on self-reported physical function in intensive care unit (ICU) patients with necrotising soft tissue infection (NSTI).
Methods
We randomised 100 patients with NSTI 1:1 to masked infusion of 25 g of IVIG (Privigen, CSL Behring) or an equal volume of 0.9% saline once daily for the first 3 days of ICU admission. The primary outcome was the physical component summary (PCS) score of the 36-item short form health survey (SF-36) 6 months after randomisation; patients who had died were given the lowest possible score (zero).
Results
Of the 100 patients randomised, 87 were included in the intention-to-treat analysis of the PCS score, 42 patients (84%) in the IVIG group and 45 patients (90%) in the placebo group. The two intervention groups had similar baseline characteristics with the exception of IVIG use before randomisation (1 dose was allowed) and rates of acute kidney injury. Median PCS scores were 36 (interquartile range 0–43) in the group assigned to IVIG and 31 (0–47) in the group assigned to placebo (mean adjusted difference 1 (95% confidence interval −7 to 10), p = 0.81). The result was supported by analyses adjusted for baseline prognostics, those in the per protocol populations, in the subgroups (site of NSTI) and those done post hoc adjusted for IVIG use before randomisation.
Conclusions
In ICU patients with NSTI, we observed no apparent effects of adjuvant IVIG on self-reported physical functioning at 6 months.
Trial registration: NCT02111161.
Similar content being viewed by others
References
Hakkarainen TW, Burkette Ikebata N, Bulger E, Evans HL (2014) Moving beyond survival as a measure of success: understanding the patient experience of necrotizing soft-tissue infections. J Surg Res 192:143–149
Hansen MB, Rasmussen LS, Garred P et al (2016) Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study. Crit Care 20:40
Eckmann C (2016) The importance of source control in the management of severe skin and soft tissue infections. Curr Opin Infect Dis 29:139–144
Valiquette L, Low DE, Chow R, McGeer AJ (2006) A survey of physician’s attitudes regarding management of severe group A streptococcal infections. Scand J Infect Dis 38:977–982
de Prost N, Sbidian E, Chosidow O et al (2015) Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey. Intensive Care Med 41:1506–1508
Takei S, Arora YK, Walker SM (1993) Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest 91:602–607
Norrby-Teglund A, Kaul R, DE Low et al (1996) Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 156:3057–3064
Sriskandan S, Ferguson M, Elliot V et al (2006) Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 58:117–124
Darenberg J, Ihendyane N, Sjölin J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333–340
Kaul R, McGeer A, Norrby-Teglund A et al (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome–a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28:800–807
Mehta S, McGeer A, Low DE et al (2006) Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 130:1679–1686
Linnér A, Darenberg J, Sjölin J et al (2014) Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 59:851–857
Carapetis JR, Jacoby P, Carville K et al (2014) Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 59:358–365
Kadri SS, Swihart BJ, Bonne SL et al (2017) Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity-score matched analysis from 130 US hospitals. Clin Infect Dis 64:877–885
Cavazzuti I, Serafini G, Busani S et al (2014) Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med 40:1888–1896
Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869
Madsen MB, Lange T, Hjortrup PB, Perner A (2016) Immunoglobulin for necrotising soft tissue infections (INSTINCT): protocol for a randomised trial. Dan Med J 63:A5250
Brook I, Frazier EH (1995) Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 33:2382–2387
Maurish ME (2011) User’s manual for the SF-36v2 health survey, 3rd edn. Quality Metric, Lincoln
Chrispin PS, Scotton H, Rogers J et al (1997) Short Form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire. Anaesthesia 52:15–23
Black NA, Jenkinson C, Hayes JA et al (2001) Review of outcome measures used in adult critical care. Crit Care Med 29:2119–2124
Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124
Haase N, Wetterslev J, Winkel P, Perner A (2013) Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial. Intensive Care Med 39:2126–2134
Perner A, Haase N, Guttormsen AB et al (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134
Schmidt K, Worrack S, Von Korff M et al (2016) Effect of a primary care management intervention on mental health-related quality of life among survivors of sepsis: a randomized clinical trial. JAMA 315:2703–2711
Paratz JD, Kenardy J, Mitchell G et al (2014) IMPOSE (IMProving Outcomes after Sepsis)-the effect of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis syndromes-a double-blinded randomised controlled trial: protocol. BMJ Open 4:e004966
Wittbrodt P, Haase N, Butowska D et al (2013) Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial. Crit Care 17:R58
Diehr P, Patrick DL, Spertus J et al (2001) Transforming self-rated health and the SF-36 scales to include death and improve interpretability. Med Care 39:670–680
Rygård SL, Holst LB, Wetterslev J et al (2016) Long-term outcomes in patients with septic shock transfused at a lower versus a higher haemoglobin threshold: the TRISS randomised, multicentre clinical trial. Intensive Care Med 42:1685–1694
Montori VM, Permanyer-Miralda G, Ferreira-González I et al (2005) Validity of composite end points in clinical trials. BMJ 330:594–596
Diep BA, Le VTM, Badiou C et al (2016) IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med 8:357ra124
ClinicalTrials.gov (2016) Effectiveness of intravenous immunoglobulins (IVIG) in toxic shock syndromes in children. https://clinicaltrials.gov/ct2/show/NCT02899702?term=NCT02899702&rank=1. Accessed 23 Nov 2016
Goscinski G, Tano E, Thulin P et al (2006) Release of SpeA from Streptococcus pyogenes after exposure to penicillin: dependency on dose and inhibition by clindamycin. Scand J Infect Dis 38:983–987
Chevret S, Seaman S, Resche-Rigon M (2015) Multiple imputation: a mature approach to dealing with missing data. Intensive Care Med 41:348–350
Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801
Kellum JA, Lameire N (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204
Acknowledgements
We are grateful to the doctors and nurses at Copenhagen University Hospital, Rigshospitalet, to the research staff at the ICU and to the INFECT team for their important contributions and to patients and relatives for their consent to participate.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The INSTINCT trial was supported by CSL Behring in the form of trial medication and a research grant for trial conduct, a research nurse and the statistical analyses. CSL Behring had no role in study design, data collection, analysis or interpretation, or writing of the report. MBM and AP conceived the idea and wrote the trial protocol. The trial group has no obligations to CSL Behring, and none of the authors have affiliations to or receive honoraria or funds from CSL Behring. The trial is part of the INFECT project (NCT01790698), supported by the European Union’s Seventh Framework Programme.
The Department of Intensive Care, Rigshospitalet, receives research funds from Fresenius Kabi, Germany, and Ferring Pharmaceuticals, Denmark.
Additional information
Take-home message: Treatment with adjuvant intravenous polyspecific immunoglobulin G in patients admitted to the intensive care unit with necrotising soft tissue infections did not improve physical quality of life in the randomised, blinded, placebo-controlled INSTINCT trial.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Madsen, M.B., Hjortrup, P.B., Hansen, M.B. et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med 43, 1585–1593 (2017). https://doi.org/10.1007/s00134-017-4786-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-017-4786-0